Department of Renal Medicine, Flinders Medical Centre, Flinders Drive, Bedford Park, Adelaide, SA, 5042, Australia.
Flinders Health and Medical Research Institute (FHMRI), College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
BMC Urol. 2022 Jul 21;22(1):112. doi: 10.1186/s12894-022-01065-w.
Kidney cancer accounts for 2% of new cancers diagnosed in Australia annually. Partial and radical nephrectomy are the treatment of choice for kidney cancer. Nephrectomy is also performed for living donor kidney transplantation. Nephrectomy is a risk factor for new-onset chronic kidney disease (CKD) or deterioration of pre-existing CKD. Understanding the risk factors for new-onset or deterioration of existing CKD after nephrectomy is important in developing preventive measures to provide better care for these patients. There is also a need to understand the incidence, natural history, management trends, and sequelae of radiofrequency ablation as well as surveillance of small renal cancers or small renal masses (SRMs). Clinical registries are critical in providing excellent patient-centre care and clinical research as well as basic science research. Registries evaluate current practice and guide future practice. The Flinders Kidney Health Registry will provide the key information needed to assess various treatment outcomes of patients with kidney cancer and patients who underwent nephrectomy for other reasons. The registry aims to provide clinical decision makers with longitudinal data on patient outcomes, health systems performance, and the effect of evolving clinical practice. The registry will also provide a platform for large-scale prospective clinical studies and research.
Patients above the age of 18 undergoing nephrectomy or radiofrequency ablation for any indication and patients with SRMs will be included in the registry. Demographic, clinical and quality of life data will be collected from hospital information systems and directly from the patient and/or caregiver.
The Registry will report a summary of patient characteristics including indication for treatment, clinical risk profiles, surgical and oncological outcomes, the proportion of patients who progress to CKD and end stage kidney disease, quality of life post treatment as well as other relevant outcomes for all patients who have undergone nephrectomy for any indication, ablation or surveillance for SRMs. The registry will record the follow-up practice after nephrectomy and patient on active surveillance, which will help to develop and enhance a best practice protocol. The collected prospective data will provide a platform for ongoing patient-orientated research and improve patient-centred healthcare delivery.
在澳大利亚,每年新诊断出的癌症中,肾癌约占 2%。部分肾切除术和根治性肾切除术是治疗肾癌的首选方法。肾切除术也用于活体供肾移植。肾切除术是新发慢性肾脏病(CKD)或原有 CKD 恶化的危险因素。了解肾切除术后新发或原有 CKD 的危险因素对于制定预防措施以更好地为这些患者提供护理非常重要。还需要了解射频消融术的发生率、自然病史、管理趋势和后果,以及小肾癌或小肾肿块(SRM)的监测。临床登记册在提供卓越的以患者为中心的护理和临床研究以及基础科学研究方面至关重要。登记册评估当前的实践并指导未来的实践。弗林德斯肾脏健康登记册将提供评估肾癌患者和因其他原因接受肾切除术的患者各种治疗结果所需的关键信息。该登记册旨在为临床决策者提供有关患者结局、卫生系统绩效以及不断发展的临床实践的影响的纵向数据。该登记册还将为大规模前瞻性临床研究和研究提供平台。
将登记患有任何疾病而行肾切除术或射频消融术的 18 岁以上患者以及患有 SRM 的患者。将从医院信息系统以及直接从患者和/或护理人员收集人口统计学、临床和生活质量数据。
该登记册将报告患者特征的摘要,包括治疗的适应症、临床风险概况、手术和肿瘤学结果、进展为 CKD 和终末期肾病的患者比例、治疗后生活质量以及接受任何适应症的肾切除术、消融术或 SRM 监测的所有患者的其他相关结果。该登记册将记录肾切除术后的随访实践以及处于积极监测中的患者,这将有助于制定和增强最佳实践方案。所收集的前瞻性数据将为正在进行的以患者为导向的研究提供平台,并改善以患者为中心的医疗保健服务。